Cancer Patents (Class 530/828)
-
Patent number: 11773381Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: GrantFiled: September 25, 2020Date of Patent: October 3, 2023Assignee: Gem Vax & KAEL CO., LTD.Inventor: Sang Jae Kim
-
Patent number: 8524872Abstract: A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.Type: GrantFiled: May 25, 2012Date of Patent: September 3, 2013Assignee: Agensys, Inc.Inventors: Arthur B. Raitano, Aya Jakobovits, Pia M. Challita-Eid, Steven B. Kanner, Wangmao Ge, Juan J. Perez-Villar, Robert Kendall Morrison
-
Patent number: 8309096Abstract: Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.Type: GrantFiled: July 15, 2009Date of Patent: November 13, 2012Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Normand Blais, Martine Boyer, Vincent Brichard, Jamila Louahed, Denis Martin, Remi Palmantier, Clement Rioux
-
Patent number: 8114606Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.Type: GrantFiled: February 15, 2008Date of Patent: February 14, 2012Assignee: The Board of Trustees of Southern Illinois UniversityInventor: Deliang Cao
-
Patent number: 7901693Abstract: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.Type: GrantFiled: October 30, 2001Date of Patent: March 8, 2011Assignee: Corixa CorporationInventors: Alexander Gaiger, Martin A Cheever
-
Patent number: 7645859Abstract: We describe a polypeptide which binds and modulates the activity of a tumour suppressor polypeptide, for example p53; a nucleic acid molecule encoding said protein and screening methods which modulate the binding activity of said polypeptide for its target polypeptide(s).Type: GrantFiled: August 13, 2004Date of Patent: January 12, 2010Assignee: Ludwig Institute For Cancer ResearchInventors: Xin Lu, Elizabeth Slee
-
Patent number: 7597894Abstract: Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions and methods that employ alternative reading frame polypeptides. ARF polypeptides and ARF polypeptide-based compositions and methods are useful in the treatment of cancer and infectious disease.Type: GrantFiled: March 5, 2004Date of Patent: October 6, 2009Assignee: Dendreon CorporationInventors: Thomas Graddis, Reiner Laus, Michael Diegel, Damir Vidovic
-
Patent number: 7511123Abstract: Novels immuno-interactive fragments of the (alpha)C portion of a mammalian inhibin alpha subunit are disclosed, together with their variants and derivatives for producing antigen-binding molecules that are interactive with said (alpha)C portion, which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.Type: GrantFiled: April 18, 2002Date of Patent: March 31, 2009Assignee: Prince Henry's Institute of Medical ResearchInventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
-
Patent number: 7479540Abstract: Adipomodulin (a light chain molecule) and related molecules and methods useful in the treatment of obesity and obesity-related disorders.Type: GrantFiled: April 5, 2005Date of Patent: January 20, 2009Inventors: Chandan Prasad, Julio E. Figueroa, II, Parakat Vijayagopal
-
Patent number: 7396904Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.Type: GrantFiled: November 29, 2004Date of Patent: July 8, 2008Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Hans Georg Rammensee, Stefan Stevanovic
-
Patent number: 7393921Abstract: The present invention relates to novel prostate specific nucleic acid molecules and polypeptides and related methods for diagnosing or predicting susceptibility to a prostate neoplastic condition.Type: GrantFiled: December 4, 2000Date of Patent: July 1, 2008Assignee: Institute for Systems BiologyInventor: Biaoyang Lin
-
Patent number: 7351793Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: April 22, 2002Date of Patent: April 1, 2008Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
-
Patent number: 7342099Abstract: Nucleic acids that encode novel polypeptides, designated in the present application as “BOG” (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-?1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided.Type: GrantFiled: February 5, 2004Date of Patent: March 11, 2008Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Snorri S. Thorgeirsson, Joseph T. Woitach, Minghuang Zhang
-
Patent number: 7329410Abstract: A method for enhancing or inducing an immune response to WT1 is disclosed. In particular, the method comprises administering to a patient an immunogenic composition comprising an isolated polypeptide consisting of amino acids 1-249 of WT1 and a non-specific immune response enhancer.Type: GrantFiled: October 9, 2000Date of Patent: February 12, 2008Assignees: Corixa Corporation, University of WashingtonInventors: Alexander Gaiger, Martin A. Cheever
-
Patent number: 7317086Abstract: This invention provides for a tumor suppressor gene inactivation of which is a causal factor in nevoid basal cell carcinoma syndrome and various sporadic basal cell carcinomas. The NBCCS gene is a homologue of the Drosophila patched (ptc) gene.Type: GrantFiled: November 22, 2002Date of Patent: January 8, 2008Assignee: United States of America as represented by the Department of Health and Human ServicesInventors: Michael C. Dean, Heidi Eve Hahn, Carol Wicking, Jeffrey Christiansen, Peter G. Zaphiropoulos, Mae R. Gailani, Susan M. Shanley, Abirami Chidambaram, Igor Vorechovsky, Erika Holmberg-Lindstrom, Anne B. Unden, Susan A. Gilles, Kylie Negus, Ian McLeod Smyth, Carol L. Pressman, David J. Leffell, Bernard Gerrard, Alisa M. Goldstein, Brandon Wainwright, Rune C. M. Toftgard, Georgia Chenevix-Trench, Allen E. Bale
-
Patent number: 7202334Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer.Type: GrantFiled: August 10, 2000Date of Patent: April 10, 2007Assignee: Corixa CorporationInventors: Jennifer L. Mitcham, Gordon E. King, Paul A. Algate, Steven P. Fling, Marc W. Retter, Gary R. Fanger, Steven G. Reed
-
Patent number: 7199218Abstract: The invention concerns a novel ICBP90 (Inverted CCAAT box binding protein 90) and its fragments, polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns methods and kits for diagnosing cell proliferation and compounds useful as medicine for preventing and/or treating pathology involving cell proliferation and in particular cancer.Type: GrantFiled: June 22, 2000Date of Patent: April 3, 2007Assignee: Institut National de la Sante et de la Recherche Medicale :(INSERM)Inventors: Christian Bronner, Raphaël Hopfner, Marc Mousli, Jean-Marc Jeltsch, Yves Lutz, Pierre Oudet
-
Patent number: 7157091Abstract: The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.Type: GrantFiled: June 18, 1999Date of Patent: January 2, 2007Assignee: Ludwig Institute for Cancer ResearchInventors: Jacques Van Snick, Bernard Lethé, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen
-
Patent number: 7115710Abstract: The present invention relates to PTP05 polypeptides and PTP10 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP05 and/or PTP10 related diseases or conditions characterized by an abnormal interaction between a PTP05 polypeptide and a PTP05 binding partner and/or a PTP10 polypeptide and a PTP10 binding partner.Type: GrantFiled: June 10, 1998Date of Patent: October 3, 2006Assignee: Sugen, Inc.Inventors: Gregory D. Plowman, Bahija Jallal
-
Patent number: 7087393Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.Type: GrantFiled: August 22, 2003Date of Patent: August 8, 2006Assignee: Abbott LaboratoriesInventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Mark A. Hayden, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe
-
Patent number: 6919435Abstract: The monoclonal antibody produced by a hybridoma cell strain TRD-L1, -L2 or -L3 which is obtained by the fusion between mouse myeloma cells and spleen cells of a mouse immunized with a human lung adenocarcinoma cell secretion component reacts in a specific fashion with a glycoprotein antigen that has a moecular weight of 200 kD or more (SDS-PAGE) and is present in human lung adenocarcinoma cells. It can be used efficiently in cancer diagnosis.Type: GrantFiled: July 12, 1999Date of Patent: July 19, 2005Assignee: Fujirebio Inc.Inventors: Kouichi Tsuji, Yoshihiro Yoshida, Takashi Uwano
-
Patent number: 6858709Abstract: Rbx1, an evolutionarily conserved Cullin-interacting RING-H2 finger protein, has been discovered. Mammalian Rbx1 has been identified as a component of the CUL2-containing VHL complex. An Rbx1 homolog from S. cerevisiae has also been identified as a subunit and activator of the Cdc53-containing SCFCdc4 ubiquitin ligase required for ubiquitination of the cdk inhibitor Sic1 and for the G1/S cell cycle transition in yeast, providing a link between the multiprotein VHL tumor suppressor complex and cellular ubiquitination. The Rbx1 protein acts as a cellular marker useful (1) in detecting a possible predisposition to certain carcinomas, (2) as a molecular target for treating those carcinomas therapeutically. (3) as a target for inhibition by drugs that manipulate the growth of cells, and (4) as a research tool to better understand the various complex mechanisms of cell ubiquitination, binding of certain activator proteins, fibronectin deposition and other aspects of the cellular division process.Type: GrantFiled: February 25, 2000Date of Patent: February 22, 2005Assignee: Oklahoma Medical Research FoundationInventors: Joan W. Conaway, Ronald C. Conaway, Takumi Kamura
-
Patent number: 6809179Abstract: Tumor-associated antigens, immunogenic peptides derived therefrom and DNA molecules coding therefor, and the use thereof in the immunotherapy of cancers.Type: GrantFiled: August 3, 2000Date of Patent: October 26, 2004Assignee: Boehringer Ingelheim International GmbHInventors: Renate Konopitzky, Ulrich Koenig, Wolfgang Sommergruber, Thomas Woelfel
-
Patent number: 6773707Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: August 10, 2000Date of Patent: August 10, 2004Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
-
Patent number: 6767711Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: GrantFiled: August 13, 2001Date of Patent: July 27, 2004Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6761892Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: April 20, 2000Date of Patent: July 13, 2004Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
-
Patent number: 6756477Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as breast cancer, are disclosed. Compositions may comprise one or more breast tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a breast tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as breast cancer. Diagnostic methods based on detecting a breast tumor protein, or mRNA encoding such a protein, in a sample are also provided.Type: GrantFiled: June 8, 2000Date of Patent: June 29, 2004Assignee: Corixa CorporationInventors: Yuqiu Jiang, Davin C. Dillon, Jennifer L. Mitcham, Jiangchun Xu, Susan L. Harlocker
-
Patent number: 6719974Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: October 5, 2000Date of Patent: April 13, 2004Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
-
Patent number: 6676934Abstract: A composition is described. The composition comprises i) a compound comprising a sulphamate group (“a sulphamate compound”); and ii) a biological response modifier.Type: GrantFiled: November 28, 2000Date of Patent: January 13, 2004Assignee: Sterix LimitedInventors: Michael John Reed, Barry Victor Lloyd Potter
-
Patent number: 6669946Abstract: The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.Type: GrantFiled: December 11, 2001Date of Patent: December 30, 2003Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethe
-
Patent number: 6663868Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: February 13, 1998Date of Patent: December 16, 2003Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
-
Patent number: 6660834Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.Type: GrantFiled: October 23, 2002Date of Patent: December 9, 2003Assignee: Abbott LaboratoriesInventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Mark A. Hayden, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe
-
Patent number: 6656480Abstract: Compositions and methods for the detection and therapy of breast cancer are disclosed. The compounds provided include nucleotide sequences that are preferentially expressed in breast tumor tissue, as well as polypeptides encoded by such nucleotide sequences. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for the prevention and treatment of breast cancer. The polypeptides may also be used for the production of antibodies, which are useful for diagnosing and monitoring the progression of breast cancer in a patient.Type: GrantFiled: October 28, 1999Date of Patent: December 2, 2003Assignee: Corixa CorporationInventors: Marc W. Retter, Davin C. Dillon
-
Patent number: 6488931Abstract: Compositions and methods for the therapy of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors.Type: GrantFiled: June 23, 1999Date of Patent: December 3, 2002Assignee: Corixa CorporationInventors: Jennifer L. Mitcham, Tony N. Frudakis, Gordon E. King
-
Patent number: 6433149Abstract: Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: GrantFiled: May 5, 1999Date of Patent: August 13, 2002Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Patent number: 6410027Abstract: The present invention relates to methods for preparing immunogenic, prophylactically and therapeutically effective complexes of heat shock proteins noncovalently associated with antigenic peptides of cancer cells. The claimed methods comprise the constructing of a cDNA library from cancer or preneoplastic cell RNA, expressing the cDNA library in an appropriate host cell, and recovering the immunogenic complexes from the cells. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the cDNA library. The complexes can be used as a vaccine to elicit specific immune responses against cancer or preneoplastic cells, and to treat or prevent cancer.Type: GrantFiled: July 23, 1999Date of Patent: June 25, 2002Assignee: Fordham UniversityInventor: Pramod K. Srivastava
-
Patent number: 6410026Abstract: The present invention relates to methods for preparing immunogenic, prophylactically and therapeutically effective complexes of heat shock proteins noncovalently associated with antigenic peptides of cancer cells. The claimed methods comprise the constructing of a cDNA library from cancer or preneoplastic cell RNA, expressing the cDNA library in an appropriate host cell, and recovering the immunogenic complexes from the cells. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the cDNA library. The complexes can be used as a vaccine to elicit specific immune responses against cancer or preneoplastic cells, and to treat or prevent cancer.Type: GrantFiled: July 23, 1999Date of Patent: June 25, 2002Assignee: Fordham UniversityInventor: Pramod K. Srivastava
-
Patent number: 6406700Abstract: The present invention relates to methods for preparing immunogenic, prophylactically and therapeutically effective complexes of heat shock proteins noncovalently associated with antigenic peptides of cancer cells. The claimed methods comprise the constructing of a cDNA library from cancer or preneoplastic cell RNA, expressing the cDNA library in an appropriate host cell, and recovering the immunogenic complexes from the cells. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the cDNA library. The complexes can be used as a vaccine to elicit specific immune responses against cancer or preneoplastic cells, and to treat or prevent cancer.Type: GrantFiled: July 23, 1999Date of Patent: June 18, 2002Assignee: Fordham UniversityInventor: Pramod K. Srivastava
-
Patent number: 6372473Abstract: The present invention relates to a novel t-PALP protein which is a member of the serine protease family. In particular, isolated nucleic acid molecules are provided encoding the human t-PALP protein. t-PALP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of t-PALP activity. Also provided are diagnostic methods for detecting circulatory system-related disorders and therapeutic methods for treating circulatory system-related disorders.Type: GrantFiled: October 4, 1999Date of Patent: April 16, 2002Assignee: Human Genome Sciences, Inc.Inventors: Paul A. Moore, Steven M. Ruben, Reinhard Ebner
-
Patent number: 6326464Abstract: Proteins derived from the product of tumor suppressor gene p53 and having enhanced functions for therapeutical use are disclosed. The proteins advantageously have enhanced tumour suppressor and programmed cell death inducer functions, particularly in proliferative disease contexts where wild-type p53 protein is inactivated. Nucleic acids coding for such molecules, vectors containing same, and therapeutical use thereof, particularly in gene therapy, are also disclosed.Type: GrantFiled: February 20, 1998Date of Patent: December 4, 2001Assignee: Aventis Pharma S.A.Inventors: Emmanuel Conseiller, Laurent Bracco
-
Patent number: 6284873Abstract: The present invention provides a novel complex of hK2 and PI-6 and methods of using the novel complex. The novel complexes of hK2 and PI-6 of the present invention exist at an elevated level in prostate cancer tissues. Therefore, the hK2-PI6 complexes of the present invention may be used as a serum marker for detecting prostate cancer. They may also be used as an immunohistological marker to detect prostate cancer tissues. In accordance with the present invention, the hK2-PI6 complexes of the present invention may be detected in patient tissue samples by immunohistochemical and/or in patient fluid samples by in vitro immunoassay procedures. Diagnostic kits and diagnostic methods for detecting the existence of prostate cancer are also provided.Type: GrantFiled: March 12, 1999Date of Patent: September 4, 2001Assignee: Hybritech IncorporatedInventors: Stephen D. Mikolajczyk, Mohammad S. Saedi
-
Patent number: 6258779Abstract: The present invention provides the methods to isolate the proteins specifically induced apoptosis (programmed cell death) in prostate cancer cells (LNCAP), leukemia cells (HL-60), and breast cancer cells (MCF-70), but without effect in normal human lung fibroblast cells (CCD 39 Lu). P-1 has no effect on breast cancer cells. Five proteins have been isolated from the conditioned media of culture cells: (1) Apogen P-1: the proteins (Apogen P-1a, Apogen P-1b and Apogen P-1c) isolated from the conditioned medium of XC cells are able to induce apoptosis in prostate cancer cells (LNCAP) without effect in normal human lung fibroblast (CCD 39 Lu), colon cancer (T84), breast cancer (MCF-7) and leukemia (HL-60) cells. (2) Apogen P-2: the protein isolated from the conditioned medium of C3H1OT1/2 cells is able to induce apoptosis in prostate cancer cells (LNCAP) and breast cancer (MCF-7) without effect in normal human lung fibroblast (CCD 39 Lu) and colon cancer (T84) cells.Type: GrantFiled: October 7, 1999Date of Patent: July 10, 2001Inventors: David Tsai, Jenny Yu
-
Patent number: 6238876Abstract: Methods for detection of the onset or presence of sporadic basal cell carcinoma in an animal by measuring for elevated levels of ectopic expression of Gli1 in the animal's epidermal tissue sample suspected of harboring sporadic basal cell carcinoma.Type: GrantFiled: June 22, 1998Date of Patent: May 29, 2001Assignee: New York UniversityInventor: Ariel Ruiz i Altaba
-
Patent number: 6174858Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).Type: GrantFiled: November 17, 1998Date of Patent: January 16, 2001Assignee: Merck & Co., Inc.Inventors: Stephen F. Brady, Dong-Mei Feng, Victor M. Garsky
-
Patent number: 6172191Abstract: The method to isolate a protein, designated as p10, which strongly inhibits the activity of H-Ras bound to GTP in vitro while in the presence of cAMP, which inactivates the biological function of Ras is provided. Protein p10 also inhibits intrinsic GTPase activity of Ras without affecting GTP binding activity in vitro, which keeps Ras in its active form and activates Ras biologically. The invention activates or inhibits Ras in a cAMP dependent manner leading to the stimulation or inhibition of cell proliferation.Type: GrantFiled: April 24, 1998Date of Patent: January 9, 2001Inventors: David Tsai, Jenny Yu
-
Patent number: 6168793Abstract: The present invention relates to compositions comprising a population of non-covalent heat shock protein 70-peptide complexes purified from mammalian tumor tissues or mammalian cells infected with an infectious agent. When administered to a mammal, the compositions are capable of eliciting an immune response. The compositions are also useful for treatment of cancer and infectious diseases in animals.Type: GrantFiled: June 5, 1995Date of Patent: January 2, 2001Assignee: Mount Sinai School of Medicine of New York UniversityInventor: Pramod K. Srivastava
-
Patent number: 6166178Abstract: The invention provides compositions and methods related to telomerase reverse transcriptase, the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: November 19, 1997Date of Patent: December 26, 2000Assignees: University Technology Corporation, Geron CorporationInventors: Thomas R. Cech, Joachim Lingner
-
Patent number: 6149921Abstract: The invention provides novel uses for n-glycolylated gangliosides and N-acetylated gangliosides, or derivatives and/or oligosaccharides thereof The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to carriers and may be accompanied by adjuvants. The vaccine compositions can be used in the treatment of breast cancers, whereby the gangliosides are used to elicit an immune response to corresponding gangliosides on breast tumor cells.Type: GrantFiled: April 17, 1998Date of Patent: November 21, 2000Assignee: Centro de Inmunologia MolecularInventors: Rolando Perez Rodriguez, Luis Enrique Fernandez Molina, Gilda Marquina Rodriguez, Adriana Carr Perez, Oscar Gonzalo Valiente Hernandez
-
Patent number: 6143507Abstract: Disclosed is a high throughput compatible assay that is useful for the identification of specific antagonists of TRAF-receptor interactions. The modular flexibility of the assay makes it possible to introduce simple modifications in order to measure the interaction of any TNF receptor cytoplasmic domain (or TRAF-binding protein) with any of the six TRAF proteins, TRAF1, TRAF2, TRAF3, TRAF4, TRAF5 and TRAF6.Type: GrantFiled: October 29, 1998Date of Patent: November 7, 2000Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Marilyn R. Kehry, Steven S. Pullen, James J. Crute
-
Patent number: RE40948Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.Type: GrantFiled: October 24, 2001Date of Patent: October 27, 2009Assignees: The Johns Hopkins University, Astrazeneca United Kingdom, Ltd., Cancer Institute, Japanese, Foundation for Cancer Research, The University of UtahInventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakumura, Andrew Thliveris, Raymond White